Chemical.AI
Provides a revolutionary research tool to combine AI with Chemistry.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $14.0m | Series B | |
| Total Funding | 000k | ||
| USD | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 11 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Chemical.AI, founded in 2018 by Dr. Ning Xia, is a technology firm that leverages artificial intelligence and automation to innovate the chemical synthesis process. Dr. Xia's journey began as early as 2008 when he developed a demo version of a data-based retrosynthesis concept in France. After returning to China in 2016, he refined the algorithm, leading to the establishment of Chemical.AI. The company is dedicated to improving the efficiency of new drug discovery for pharmaceutical companies by addressing challenges in preclinical chemical synthesis.
The firm operates on a B2B model, providing advanced cheminformatics and automated solutions to over 100 clients in the pharmaceutical, materials, biomedicine, and chemical engineering sectors, including major pharmaceutical companies and contract research organizations (CROs). Its client base spans Asia, Europe, and North America. Revenue is generated through its comprehensive suite of products and services that digitize and accelerate research and development. The company has secured significant financial backing, raising a total of $33.7M through multiple funding rounds, including a Series A led by Sequoia China Seed Fund and a Series B round raising nearly $14 million.
The core of Chemical.AI's offering is its ChemFamily suite, which includes ChemAIRS®, ChemAIOS, and ChemAIoT. ChemAIRS® is an AI-powered platform for designing retrosynthesis routes, capable of generating multiple viable synthetic pathways for a target molecule in minutes by considering factors like reaction feasibility and chiral synthesis strategies. This platform is supplemented by features such as synthesizability assessment and impurity prediction. ChemAIOS is an intelligent lab management system for digitalizing workflows, while ChemAIoT integrates robotics to create automated solutions for the entire experimental process. In 2021, the company launched its Automated Intelligence Laboratory (ChemAILAB®), a high-throughput synthesis facility that combines AI with robotics to enhance synthesis efficiency.
Keywords: chemical synthesis, retrosynthesis, artificial intelligence, cheminformatics, drug discovery, lab automation, process chemistry, reaction informatics, pharmaceutical R&D, medicinal chemistry, high-throughput synthesis, molecular design, AI-powered chemistry, synthesis planning, CRO services, ChemAIRS, Ning Xia, computational chemistry, reaction prediction, chemical data